Subscribe to RSS
DOI: 10.1055/s-2006-931470
Combined Treatment with Citalopram and Buspirone: Effects on Serotonin 5-HT2A and 5-HT2C Receptors in the Rat Brain
Publication History
Received: 14.3.2005
Revised: 19.7.2005
Accepted: 30.8.2005
Publication Date:
02 February 2006 (online)
![](https://www.thieme-connect.de/media/pharmaco/200601/lookinside/thumbnails/10.1055-s-2006-931470-1.jpg)
Introduction: We wanted to elucidate whether the proposed advantages of citalopram-buspirone combination treatment are related to changes in 5-HT2A/C receptor-mediated neurotransmission. Methods: The affinity of buspirone to 5-HT2A and 5-HT2C receptors was measured in vitro, and the influence of buspirone on 5-HT2C receptor-mediated phosphoinositide hydrolysis was estimated. Four groups of rats received citalopram (10 mg/kg), buspirone (6 mg/kg), citalopram-buspirone combination, or saline once a day s. c. for 14 days. Treatment effects on 5-HT2A and 5-HT2C receptors were investigated by receptor autoradiography with antagonist and agonist radioligands. Results: Buspirone was found to be a weak 5-HT2C receptor antagonist, with a low affinity for 5-HT2A and 5-HT2C receptors. Repeated buspirone-citalopram combination treatment markedly decreased [3H]ketanserin and [125I]DOI binding to 5-HT2A receptors. Repeated administration of buspirone and buspirone-citalopram combination increased the affinity of [3H]mesulergine toward 5-HT2C receptors, and buspirone-citalopram combination also decreased [125I]DOI binding to 5-HT2C receptors. Discussion: We suggest that downregulation of brain 5-HT2A receptors and possibly of 5-HT2C receptor agonist sites is involved in the beneficial clinical effects of buspirone-SSRI augmentation treatment. Furthermore, a conversion of brain 5-HT2C receptors from high- to low-affinity state may provide an additional mechanism for the anti-anxiety effects of buspirone.
Abbreviations
Bmax:maximum receptor density
DOI:(+-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane
5-HT:serotonin (5-hydroxytryptamine)
IP:inositol monophosphate
K d:equilibrium dissociation constant (affinity)
K i:inhibition constant
KRB:Krebs-bicarbonate
PI:phosphoinositide
1-PP:1-(2-pyrimidinyl)piperazine
SSRI:selective serotonin reuptake inhibitor
References
- 1 Appel N M, Mitchell W M, Garlick R K, Glennon R A, Teitler M, De Souza E B. Autoradiographic characterization of (+-)-1-(2,5-dimethoxy-4-[125I] iodophenyl)-2-aminopropane ([125I]DOI) binding to 5-HT2 and 5-HT1c receptors in rat brain. J Pharmacol Exp Ther. 1990; 255 843-857
- 2 Appelberg B G, Syvälahti E K, Koskinen T E, Mehtonen O P, Muhonen T T, Naukkarinen H H. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study. J Clin Psychiatry. 2001; 62 448-452
- 3 Ashby C RJ, Edwards E, Wang R Y. Electrophysiological evidence for a functional interaction between 5-HT1A and 5-HT2A receptors in the rat medial prefrontal cortex: an iontophoretic study. Synapse. 1994; 17 173-181
- 4 Aznar S, Qian Z, Shah R, Rahbek B, Knudsen G M. The 5-HT1A serotonin receptor is located on calbindin- and parvalbumin-containing neurons in the rat brain. Brain Res. 2003; 959 58-67
- 5 Baldwin D, Rudge S. The role of serotonin in depression and anxiety. Int Clin Psychopharmacol. 1995; 9 41-45
- 6 Barker E L, Westphal R S, Schmidt D, Sanders-Bush E. Constitutively active 5-hydroxytryptamine2C receptors reveal novel inverse agonist activity of receptor ligands. J Biol Chem. 1994; 269 11 687-11 690
- 7 Blier P, Ward N M. Is there a role for 5-HT1A agonists in the treatment of depression?. Biol Psychiatry. 2003; 53 193-203
- 8 Bouwer C, Stein D J. Buspirone is an effective augmenting agent of serotonin selective reuptake inhibitors in severe treatment-refractory depression. S Afr Med J. 1997; 87 534-537, 540
- 9 Dhaenen H. Imaging the serotonergic system in depression. Eur Arch Psychiatry Clin Neurosci. 2001; 251 1176-1180
- 10 Dimitriou E C, Dimitriou C E. Buspirone augmentation of antidepressant therapy. J Clin Psychopharmacol. 1998; 18 465-469
- 11 Dolberg O T, Klag E, Gross Y, Schreiber S. Relief of serotonin selective reuptake inhibitor induced sexual dysfunction with low-dose mianserin in patients with traumatic brain injury. Psychopharmacology (Berl). 2002; 161 404-407
- 12 Egan C, Grinde E, Dupre A, Roth B L, Hake M, Teitler M, Herrick-Davis K. Agonist high and low affinity state ratios predict drug intrinsic activity and a revised ternary complex mechanism at serotonin 5-HT(2A) and 5-HT(2C) receptors. Synapse. 2000; 35 144-150
- 13 Fava M. Augmentation and combination strategies in treatment-resistant depression. J Clin Psychiatry. 2001; 62 4-11
- 14 Frank E, Karp J F, Rush A J. Efficacy of treatments for major depression. Psychopharmacol Bull. 1993; 29 457-475
- 15 Gibson E L, Barnfield A M, Curzon G. Evidence that mCPP-induced anxiety in the plus-maze is mediated by postsynaptic 5-HT2C receptors but not by sympathomimetic effects. Neuropharmacology. 1994; 33 457-465
- 16 Gobert A, Rivet J M, Cistarelli L, Melon C, Millan M J. Alpha2-adrenergic receptor blockade markedly potentiates duloxetine- and fluoxetine-induced increases in noradrenaline, dopamine, and serotonin levels in the frontal cortex of freely moving rats. J Neurochem. 1997; 69 2616-2619
- 17 Gobert A, Rivet J M, Cistarelli L, Melon C, Millan M J. Buspirone modulates basal and fluoxetine-stimulated dialysate levels of dopamine, noradrenaline and serotonin in the frontal cortex of freely moving rats: activation of serotonin1A receptors and blockade of alpha2-adrenergic receptors underlie its actions. Neuroscience. 1999; 93 1251-1262
- 18 Golembiowska K, Dziubina A. Effect of acute and chronic administration of citalopram on glutamate and aspartate release in the rat prefrontal cortex. Pol J Pharmacol. 2000; 52 441-448
- 19 Graeff F G, Guimaraes F S, De Andrade T G, Deakin J F. Role of 5-HT in stress, anxiety, and depression. Pharmacol Biochem Behav. 1996; 54 129-141
- 20 Gray J A, Roth B L. Paradoxical trafficking and regulation of 5-HT(2A) receptors by agonists and antagonists. Brain Res Bull. 2001; 56 441-451
- 21 Haddjeri N, Blier P, de Montigny C. Long-term antidepressant treatments result in a tonic activation of forebrain 5-HT1A receptors. J Neurosci. 1998; 18 10 150-10 156
- 22 Harvey K V, Balon R. Augmentation with buspirone: a review. Ann Clin Psychiatry. 1997; 7 143-147
- 23 Hietala J, Salonen I, Lappalainen J, Syvälahti E. Ethanol administration does not alter dopamine D1 and D2 receptor characteristics in rat brain. Neurosci Lett. 1990; 108 289-294
- 24 Hjorth S, Auerbach S B. Lack of 5-HT1A autoreceptor desensitization following chronic citalopram treatment, as determined by in vivo microdialysis. Neuropharmacology. 1994; 33 331-334
- 25 Hoyer D, Clarke D E, Fozard J R, Hartig P R, Martin G R, Mylecharane E J, Saxena P R, Humphrey P P. VII. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol Rev. 1994; 46 157-203
- 26 Jenck F, Moreau J L, Mutel V, Martin J R, Haefely W E. Evidence for a role of 5-HT1C receptors in the antiserotonergic properties of some antidepressant drugs. Eur J Pharmacol. 1993; 231 223-229
- 27 Joffe R T, Schuller D R. An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression. J Clin Psychiatry. 1993; 54 269-271
- 28 Julius D, MacDermott A B, Axel R, Jessell T M. Molecular characterization of a functional cDNA encoding the serotonin 1c receptor. Science. 1988; 241 558-564
- 29 Kennett G A. 5-HT1C receptor antagonists have anxiolytic-like actions in the rat social interaction model. Psychopharmacology (Berl). 1992; 107 379-384
- 30 Klimek V, Zak-Knapik J, Mackowiak M. Effects of repeated treatment with fluoxetine and citalopram, 5-HT uptake inhibitors, on 5-HT1A and 5-HT2 receptors in the rat brain. J Psychiatry Neurosci. 1994; 19 63-67
- 31 Kuoppamäki M, Pälvimäki E P, Syvälahti E, Hietala J. 5-HT1C receptor-mediated phosphoinositide hydrolysis in the rat choroid plexus after chronic treatment with clozapine. Eur J Pharmacol. 1994; 255 91-97
- 32 Kuoppamäki M, Seppälä T, Syvälahti E, Hietala J. Regulation of serotonin 5-HT2C receptors in the rat choroid plexus after acute clozapine treatment. Eur J Pharmacol. 1994; 269 201-208
- 33 Kuoppamäki M, Syvälahti E, Hietala J. Clozapine and N-desmethylclozapine are potent 5-HT1C receptor antagonists. Eur J Pharmacol. 1993; 245 179-182
- 34 Laakso A, Pälvimäki E P, Kuoppamäki M, Syvälahti E, Hietala J. Chronic citalopram and fluoxetine treatments upregulate 5-HT2c receptors in the rat choroid plexus. Neuropsychopharmacology. 1996; 15 143-151
- 35 Lafaille F, Welner S A, Suranyi-Cadotte B E. Regulation of serotonin type 2 (5-HT2) and beta-adrenergic receptors in rat cerebral cortex following novel and classical antidepressant treatment. J Psychiatry Neurosci. 1991; 16 209-214
- 36 Landen M, Bjorling G, Agren H, Fahlen T. A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression. J Clin Psychiatry. 1998; 59 664-668
- 37 Landen M, Eriksson E, Agren H, Fahlen T. Effect of buspirone on sexual dysfunction in depressed patients treated with selective serotonin reuptake inhibitors. J Clin Psychopharmacol. 1999; 19 268-271
- 38 Lucaites V L, Nelson D L, Wainscott D B, Baez M. Receptor subtype and density determine the coupling repertoire of the 5-HT2 receptor subfamily. Life Sci. 1996; 59 1081-1095
- 39 Maj J, Moryl E. Effects of sertraline and citalopram given repeatedly on the responsiveness of 5-HT receptor subpopulations. J Neural Transm Gen Sect. 1992; 88 143-156
- 40 Marek G J, Carpenter L L, McDougle C J, Price L H. Synergistic action of 5-HT2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders. Neuropsychopharmacology. 2003; 28 402-412
- 41 Miner L A, Backstrom J R, Sanders-Bush E, Sesack S R. Ultrastructural localization of serotonin2A receptors in the middle layers of the rat prelimbic prefrontal cortex. Neuroscience. 2003; 116 107-117
- 42 Nocjar C, Roth B L, Pehek E A. Localization of 5-HT(2A) receptors on dopamine cells in subnuclei of the midbrain A10 cell group. Neuroscience. 2002; 111 163-176
- 43 Okazawa H, Yamane F, Blier P, Diksic M. Effects of acute and chronic administration of the serotonin1A agonist buspirone on serotonin synthesis in the rat brain. J Neurochem. 1999; 72 2022-2031
- 44 Onder E, Tural U. Faster response in depressive patients treated with fluoxetine alone than in combination with buspirone. J Affect Disord. 2003; 76 223-227
- 45 Paxinos G, Watson C. The rat brain in stereotaxic coordinates (4th edition). San Diego, USA; Academic Press 1998
- 46 Pazos A, Cortes R, Palacios J M. Quantitative autoradiographic mapping of serotonin receptors in the rat brain. II. Serotonin-2 receptors. Brain Res. 1985; 346 231-249
- 47 Peroutka S J, Howell T A. The molecular evolution of G protein-coupled receptors: focus on 5-hydroxytryptamine receptors. Neuropharmacology. 1994; 33 319-324
- 48 Petty F, Davis L L, Kabel D, Kramer G L. Serotonin dysfunction disorders: a behavioral neurochemistry perspective. J Clin Psychiatry. 1996; 57 Suppl 8 11-16
- 49 Pranzatelli M R. Regulation of 5-HT2 receptors in rat cortex. Studies with a putative selective agonist and an antagonist. Biochem Pharmacol. 1991; 42 1099-1105
- 50 Pälvimäki E P, Roth B L, Majasuo H, Laakso A, Kuoppamäki M, Syvälahti E, Hietala J. Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c receptor. Psychopharmacology (Berl). 1996; 126 234-240
- 51 Rickels K. Buspirone in clinical practice. J Clin Psychiatry. 1990; 51 51-54
- 52 Roth B L, Hamblin M, Ciaranello R D. Regulation of 5-HT2 and 5-HT1C serotonin receptor levels. Methodology and mechanisms. Neuropsychopharmacology. 1990; 3 427-433
- 53 Rowan M J, Anwyl R. Neurophysiological effects of buspirone and isapirone in the hippocampus: comparison with 5-hydroxytryptamine. Eur J Pharmacol. 1986; 132 93-96
- 54 Sanders-Bush E, Breeding M. Serotonin1c receptor reserve in choroid plexus masks receptor subsensitivity. J Pharmacol Exp Ther. 1990; 252 984-988
- 55 Saxena P R. Serotonin receptors: subtypes, functional responses and therapeutic relevance. Pharmacol Ther. 1995; 66 339-368
- 56 Seeman P. Receptor Tables, vol. 2: Drug dissociation constants for neuroreceptors and transporters. Toronto, Canada; SZ Research 1993
- 57 Skrebuhhova T, Allikmets L, Matto V. [3H]-ketanserin binding and elevated plus-maze behavior after chronic antidepressant treatment in DSP-4 and P-CPA pretreated rats: evidence for partial involvement of 5-HT2A receptors. Methods Find Exp Clin Pharmacol. 1999; 21 483-490
- 58 Stadel J M, De Lean A, Lefkowitz R J. Molecular mechanisms of coupling in hormone reseptor - adenylate cyclase systems. Adv Enzymol Relat Areas Mol Biol. 1982; 53 1-43
- 59 Van Oekelen D, Luyten W H, Leysen J E. 5-HT2A and 5-HT2C receptors and their atypical regulation properties. Life Sci. 2003; 72 2429-2449
- 60 VanderMaelen C P, Matheson G K, Wilderman R C, Patterson L A. Inhibition of serotonergic dorsal raphe neurons by systemic and iontophoretic administration of buspirone, a non-benzodiazepine anxiolytic drug. Eur J Pharmacol. 1986; 129 123-130
- 61 Willins D L, Deutch A Y, Roth B L. Serotonin 5-HT2A receptors are expressed on pyramidal cells and interneurons in the rat cortex. Synapse. 1997; 27 79-82
Prof. Erkka Syvälahti
Department of Pharmacology and Clinical Pharmacology
University of Turku
Itäinen Pitkäkatu 4 B
20520 Turku
FINLAND
Phone: +358 2 333 7582
Fax: +358 2 333 7216
Email: erkka.syvalahti@utu.fi